MODERN-HEALTH
Modern Health, en førende mental sundhedsplatform på det globale arbejdsmarked og Generali Health Solutions GmbH offentliggør i dag et eksklusivt partnerskab. Som udbyder af bevist effektive sundhedsprogrammer er Generali Health Solutions GmbH en del af den internationale Generali Group, som er en af de største globale udbydere af forsikringer og formueforvaltning. Dette partnerskab kommer på et tidspunkt, hvor der er et stigende behov for support af den mentale sundhed på arbejdspladsen. Depression er den førende årsag til uarbejdsdygtighed i verden med 12 milliarder mistede arbejdsdage pga. depression og angst, hvilket giver et anslået årligt tab i produktivitet på USD 1 billion. Partnerskabet gør det nu muligt for arbejdsgivere i mere end 50 lande at investere i mental sundhed for deres medarbejdere, hvilket er et stort skridt fremad i prioriteringen af mental sundhed på global skala.
“Vi er overbeviste om, at global retfærdighed i mental sundhed skal gå længere end adgang til eller appoversættelser – det skal være en integreret del af hvert enkelt aspekt i omsorg for og afspejling af hver person og deres unikke oplevelser,” siger Alyson Watson, grundlægger og adm. direktør for Modern Health. “Vi sætter enkeltpersoner i centrum for deres mentale sundhedsforløb og sikrer, at mental sundhed føles så personlig som den person, den skal hjælpe. Vi er imponerede over Generalis tilsagn til deres kunder og er beærede over at blive partner for at forbedre livet for mennesker over hele verden med ægte global og personlig mental sundhedsomsorg, der giver de bedste resultater for medlemmer, hvad der behov må være, eller hvor de bor.”
Dette samarbejde giver arbejdsgivere mulighed for nemt at få adgang til Modern Healths omfattende globale mentale sundhedsfordele på det globale arbejdsmarked via Generali Health Solutions. Dette omfatter en-til-en-support fra autoriserede terapeuter og certificerede coaches, gruppefællesskabs Circles, de første i branchen Pathways, krisesupport og en omfattende samling digitale ressourcer via selvbetjening til emotionelle, professionelle, sociale, økonomiske og fysiske velfærdsbehov – alt sammen på en platform. Modern Healths innovative og bæredygtige trindopdelte omsorgsmetode giver en solid, beviselig support for hele den globale arbejdsstyrke, der medfører målbare resultater for alle, lige meget hvad de lever med.
"Vores mål er et give vores kunder innovative løsninger, som fremmer sundhed og modstandsdygtighed på arbejdspladsen og således øge medarbejdernes produktivitet," forklarer Dr. Markus Homann, adm. direktør for Generali Health Solutions. “Vi ved, at der er et stigende behov for velfærdssupport på arbejdspladsen og ved at slå os sammen med Modern Health kan vi nemt og uden problemer forbinde vores kunder til det bedste på markedet for globale mental sundhedspleje.”
Gå til Modern Health eller Generali Health Solutions for at få mere at vide.
Om Modern Health
Modern Health er en omfattende global løsning på mental sundhed, som tilbyder medarbejdere adgang til en-til-en-, gruppe- og selvbetjenings digitale ressourcer til deres emotionelle, professionelle, sociale, økonomiske og fysiske velfærdsbehov - alt på én platform. Når en person ønsker proaktivt at håndtere stress eller behandle depression, guider Modern Health disse mennesker til den rigtige hjælp på det rigtige tidspunkt.
Modern Health støttes af investorer som Kleiner Perkins, Founders Fund, John Doerr, Y Combinator og Battery Ventures og skaffede mere end USD 170 millioner på mindre end to år, hvilket gør Modern Health til det hurtigst helt kvindegrundlagte firma i USA til at nå Unicorn-status.
Om Generali Health Solutions
Generali Health Solutions GmbH (GHS) er en del af den internationale Generali Group. Som udbyder af beviseligt effektive sundhedsprogrammer, som kan bruges i virksomheder, forsikringsselskaber og andre institutioner, skaber GHS primært løsninger, som hjælper medarbejdere med at fortsætte med at være produktive og mere tilfredse. Derudover er målet at reducere produktivitetstab og behandlingsomkostninger pga. Sygdom.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240716732760/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum